Opinion: The Burden of Proof

Universities that profit from football programs need to honestly assess their responsibilities when it comes to head injury research.

Written byDavid Rubenson and Paul Salvaterra
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

SXC.HU, SUPERCOLORLast August the National Football League (NFL) agreed to pay players $765 million to settle a lawsuit involving head trauma and neurodegenerative disease. While our understanding of head injury impacts on high school and college footballers remains incomplete, there is enough evidence to compel universities to assess their responsibilities and organize their diverse capabilities to address the problem.

Key to such an assessment is recognizing that the burden of proof varies for purposes of science and purposes of policy, and that both levels of proof are subject to significant ambiguity. Failure to grapple with these ambiguities could leave some universities sounding much like other organizations and private companies that have stubbornly denied responsibility for dangerous products.

A common deception used to refute mounting scientific evidence is to argue that the burden of proof for policy change must rise to scientific standards. However, proof for purposes of science is an elusive concept, since nearly every scientific explanation raises further questions. Throughout the 1960s, ‘70s, and ‘80s, the tobacco industry consistently refuted strong correlative evidence about smoking and lung cancer by citing gaps in mechanistic ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies